Concepedia

Patricia Marinello

PM

Statistics

Publications

45

Citations

7.5K

H-Index

26

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Institut Gustave Roussy

University of Bologna

Patricia Marinello is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, pembrolizumab therapy, and medicine.

Publications per year

1998–2023

45

Publications

45

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text

, , +17

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le, Tae Won Kim, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

, , +17

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim et al. · The Lancet Oncology · 2022 · 894 citations · Full text

, , +14

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

, , +15

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

, , +12

1–5 of 45